-
Oct 23, 2026ProTACT: A first-in-human, phase 1 study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, a PSMA-targeted radioconjugate in patients with mCRPC – Dose escalation results
Aaron Richard Hansen1*, Aviral Singh2, Stanley Ngai1, Shyam M. Srinivas3, Amanda Macaraeg3, Jeffrey Y.C. Wong4, Tanya B. Dorff4, Howard Gurney5, Alison Yan Zhang5, Robert Dreicer6, Zhi Yang7, Peng Du7, Yüksel Ürün8, Özlem Küçük8, Pedro C. Barata9, Wei Xue10, Anne Robert11, Denis V. Ferreira11, Debora Barton11, Giuseppe Cardaci2
Read More -
Jun 11, 2024Development of 177Lu-FL-091 for the treatment of NTSR1-positive cancers
Shanghai, China, and Heidelberg, Germany – June 11, 2024 – Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, released preclinical data of its NTSR1-targeting RDC program FL-091 in an oral presentation at the 2024 SNMMI (The Society of Nuclear Medicine and Molecular Imaging) Annual Meeting, held on June 8th to 11th, 2024 at Metro Toronto Convention Centre, Toronto, ON, Canada.
Read More -
Apr 10, 2024225Ac-FL-020 is a novel PSMA-targeting radionuclide drug conjugate (RDC) with superior in vivo anti-tumor activity
Full-Life Technologies Announced the Poster Presentations of preclinical data of its novel PSMA-targeted RDC program 225Ac-FL-020 at the AACR Annual Meeting 2024
Read More